Objectives: Patient knowledge deficits related to opioid risks, including lack of knowledge regarding addiction, are well documented. Our objective was to characterize patients' perceptions of signs of addiction.
Methods: This study utilized data obtained as part of a larger interventional trial. Consecutively discharged English-speaking patients, age >17 years, at an urban academic emergency department, with a new opioid prescription were enrolled from July 2015 to August 2017. During a follow-up phone interview 7 to 14 days after discharge, participants were asked a single question, "What are the signs of addiction to pain medicine?" Verbatim transcribed answers were analyzed using a directed content analysis approach and double coding. These codes were then grouped into themes.
Results: There were 325 respondents, 57% female, mean age 43.8 years, 70.1% privately insured. Ten de novo codes were added to the 11 DSM-V criteria codes. Six themes were identified: (1) effort spent acquiring opioids, (2) emotional and physical changes related to opioid use, (3) opioid use that is "not needed, (4) increasing opioid use, (5) an emotional relationship with opioids, and (6) the inability to stop opioid use.
Conclusions: Signs of addiction identified by opioid naive patients were similar to concepts identified in medical definitions. However, participants' understanding also included misconceptions, omissions, and conflated misuse behaviors with signs of addiction. Identifying these differences will help inform patient-provider risk communication, providing an opportunity for counseling and prevention.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ADM.0000000000000806 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Use of a Personalized Clinical Decision Support System for Dosing in Psychopharmacotherapy in Patients with Alcoholic Hallucinosis Based on Pharmacogenomic Markers.
Psychopharmacol Bull
January 2025
Sychev, corresponding member of the Academy of Sciences of Russia, MD, PhD, MD, professor, rector, head of clinical pharmacology and therapy department, Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation, Moscow, Russian Federation.
Introduction: Alcoholic hallucinosis (AH) is one of the severe complications of chronic alcoholism, characterized by psychotic symptoms such as auditory hallucinations and delusions. Haloperidol is widely used to treat AH; however, its therapy is often complicated by side effects. A personalized approach using pharmacogenetic testing (particularly the CYP2D6 polymorphism) allows individualization of haloperidol dosage, improving both safety and efficacy of therapy.
View Article and Find Full Text PDFPerceptions of treatment, accompanying symptoms, and other problems in patients with chronic pain: a multicenter cross-sectional study in Korea.
Korean J Pain
January 2025
Department of Anesthesiology and Pain Medicine, Konkuk University School of Medicine, Seoul, Korea.
Article Synopsis
- Chronic pain significantly impacts patients' daily lives, mental health, and relationships, leading to various concerns about treatment and its side effects.
- The study involved 833 patients from South Korea, revealing that many expressed worries about medication risks and opioid addiction, with common symptoms including irritability, depression, and sleep disturbances.
- Analysis showed that women were more prone to anxiety and depression, while men faced issues like family conflict and unemployment, highlighting that younger patients experienced more accompanying symptoms than older ones.
The Severity of the COVID-19 Among Chronic Disease Patients in the Selected Hospitals in Riyadh, Saudi Arabia - A Retrospective Study.
Risk Manag Healthc Policy
December 2024
Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Background And Aims: Chronic disease is a lifelong disorder that necessitates continuing medical care and is more prone to infections such as COVID-19, compared to healthy individuals. Therefore, this study aimed to assess the severity of COVID-19 among chronic disease patients in the Kingdom of Saudi Arabia.
Methods And Materials: A cross-sectional study was conducted in selected hospitals in the Riyadh region in Saudi Arabia, over 6 months in 2022.
Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial.
Am J Psychiatry
January 2025
Department of Psychiatry, NYU Langone Center for Psychedelic Medicine, NYU Grossman School of Medicine, New York (Pagni, Zeifman, Mennenga, Carrithers, Goldway, O'Donnell, Ross, Bogenschutz); School of Life Sciences, Arizona State University, Tempe (Mennenga); Department of Psychology, New York University, New York (Goldway); Department of Psychiatry and Behavioral Sciences, University of New Mexico School of Medicine, Albuquerque (Bhatt).
Objective: Evidence suggests that psilocybin-assisted therapy (PAT) leads to durable shifts in personality structure. However, such changes have yet to be characterized in disorders of addiction. In this secondary analysis from a randomized controlled trial, the authors examined the effect of PAT on personality dimensions in patients with alcohol use disorder (AUD), hypothesizing that PAT would attenuate personality abnormalities in AUD and that reductions in trait impulsiveness would be associated with lower drinking.
View Article and Find Full Text PDFPsilocybin: From Psychiatric Pariah to Perceived Panacea.
Am J Psychiatry
January 2025
Department of Psychiatry and Behavioral Sciences (Fonzo, Barksdale, Nemeroff) and Center for Psychedelic Research and Therapy (Fonzo, Nemeroff), University of Texas at Austin Dell Medical School, Austin; Institute for Early Life Adversity Research, University of Texas at Austin, Austin (Fonzo, Nemeroff); Department of Behavioral Health, Walter Reed National Military Medical Center, Bethesda, MD (Wolfgang); Department of Psychiatry, Uniformed Services University of the Health Sciences, Bethesda, MD (Wolfgang); Department of Psychiatry, Yale University School of Medicine, New Haven, CT (Wolfgang, Krystal); Butler Hospital, Department of Psychiatry and Human Behavior, Warren Alpert Medical School, Brown University, Providence, RI (Carpenter); Department of Psychiatry and Behavioral Neurobiology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham (Kraguljac); Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA, Los Angeles (Grzenda); Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (McDonald); Department of Psychiatry and Behavioral Sciences, University of Minnesota, Minneapolis (Widge); Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA (Rodriguez); Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (Rodriguez).
Objective: The authors critically examine the evidence base for psilocybin administered with psychological support/therapy (PST) in the treatment of psychiatric disorders and offer practical recommendations to guide future research endeavors.
Methods: PubMed was searched for English-language articles from January 1998 to November 2023, using the search term "psilocybin." A total of 1,449 articles were identified and screened through titles and abstracts.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!